Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer ..read more

The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer ..read more

Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings ..read more

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer ..read more

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS ..read more

Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer ..read more

FDA Approves FoundationOne CDx for Niraparib/Abiraterone in BRCA+ mCRPC Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD. Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer Oncology Peer Review On-The-Go: Mediterranean Diet’s Association With Localized Prostate Cancer Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy Everythi ..read more

FDA OKs Niraparib and Abiraterone Acetate for BRCA+ Metastatic CRPC Across several clinical trials, Unfold AI appears to help in prostate cancer treatment selection and follow-up. Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer Oncology Peer Review On-The-Go: Mediterranean Diet’s Association With Localized Prostate Cancer Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy Radiotherapy/ADT Prol ..read more

Treatment Algorithms with the Oncology Brothers ..read more

While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer ..read more